ArticleFrontiers in pharmacology2018
Pioglitazone Protects Against Renal Ischemia-Reperfusion Injury via the AMP-Activated Protein Kinase-Regulated Autophagy Pathway.
Article in Frontiers in pharmacology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 43 citations in OpenAlex.
- Pioglitazone reduces hepatic α-1 antitrypsin accumulation through autophagy and AMPK activation in α-1 antitrypsin-deficient mice.American journal of physiology. Gastrointestinal and liver physiology · 2025Article
- Mitochondrial dysfunction in acute kidney injury.Renal failure · 2024Review
- Regulation of renal ischemia-reperfusion injury and tubular epithelial cell ferroptosis by pparγ m6a methylation: mechanisms and therapeutic implications.Biology direct · 2024Article
- Pioglitazone ameliorates ischemia/reperfusion-induced acute kidney injury via oxidative stress attenuation and NLRP3 inflammasome.Human cell · 2024Article
- Mitochondrial quality control in acute kidney disease.Journal of nephrology · 2023Review
- The Mitochondrion: A Promising Target for Kidney Disease.Pharmaceutics · 2023Review
- Pioglitazone modulates immune activation and ameliorates inflammation induced by injured renal tubular epithelial cells via PPARγ/miRNA‑124/STAT3 signaling.Biomedical reports · 2023Article
- The effects of the voglibose on non-alcoholic fatty liver disease in mice model.Scientific reports · 2022Article
- Ozone induces autophagy by activating PPARγ/mTOR in rat chondrocytes treated with IL-1β.Journal of orthopaedic surgery and research · 2022Article
- Protective Effects of PPAROxidative medicine and cellular longevity · 2022Article
- The Role of Peroxisome Proliferator-Activated Receptors in Kidney Diseases.Frontiers in pharmacology · 2022Review
- Glitazone Treatment Rescues Phenotypic Deficits in a Fly Model of Gaucher/Parkinson's Disease.International journal of molecular sciences · 2021Article
- Mitochondrial quality control in kidney injury and repair.Nature reviews. Nephrology · 2021Review
- Pioglitazone Ameliorates Renal Ischemia-Reperfusion InjuryFrontiers in physiology · 2021Article
- PMMA-Based Continuous Hemofiltration Modulated Complement Activation and Renal Dysfunction in LPS-Induced Acute Kidney Injury.Frontiers in immunology · 2021Article
- PPARγ in Ischemia-Reperfusion Injury: Overview of the Biology and Therapy.Frontiers in pharmacology · 2021Review
- Pioglitazone attenuates advanced glycation end products-induced apoptosis and calcification by modulating autophagy in tendon-derived stem cells.Journal of cellular and molecular medicine · 2020Article
- Autophagy Function and Regulation in Kidney Disease.Biomolecules · 2020Review
- Detrimental and Beneficial Effect of Autophagy and a Potential Therapeutic Target after Ischemic Stroke.Evidence-based complementary and alternative medicine : eCAM · 2020Review
- Liraglutide promotes autophagy by regulating the AMPK/mTOR pathway in a rat remnant kidney model of chronic renal failure.International urology and nephrology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Renal ischemia-reperfusion injury (IRI) is a major cause of acute renal failure. Our previous studies have shown that pioglitazone, a peroxisome proliferators-activated receptor (PPAR)-γ agonist used in type 2 diabetes, protects against renal IRI; however, the molecular mechanism underlying the renoprotective effects of pioglitazone is still unclear. In this study, we investigated the role of AMP-activated protein kinase (AMPK)-regulated autophagy in renoprotection by pioglitazone in IRI. To investigate whether pioglitazone protects renal cells from IRI, an
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.